Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 51, Issue 2, 1996, Pages 183-187

  Koytchev, R ^a   Alken, R G ^a   McKay, G ^b   Katzarov, T ^c  

^a Coop Clin Drug R and D ^*  (Germany)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c National Oncology Center Bulgaria   (Bulgaria)

Author keywords

Bioavailability; Fluphenazine; Human; Slow release formulation

Indexed keywords

FLUPHENAZINE; FLUPHENAZINE DECANOATE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COULOMETRY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; FLUPHENAZINE; HUMANS; INJECTIONS, INTRAVENOUS; MALE;

EID: 0029848775     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050182     Document Type: Article

References (13)

1. Bircher J, Lotterer E (1988) Klinisch-Pharmakologische Datensammlung. Gustav Fischer, Stuttgart
2. Bunney BS, Aghajanian GK (1974) A comparison of the effects of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulfoxide on the activity of central dopamine neurons. Life Sci 15:309-318
3. Cooper JK, Hawes EM, Hubbard JW, McKay G, Midha KK (1989) An ultrasensitive method for the measurement of fluphenazine in plasma by high-performance liquid chromatography with coulometric detection. Ther Drug Monit 11: 354-360
4. Dahl SG (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monitor 4:33-40
5. Dailey J, Sedvall G, Sjoquist B (1972) Effect of chlorpromazine and some of its metabolites on the accumulation of homovanillic acid in brain of mice. J Pharm Pharmacol 24:580-581
6. Hauschke D, Steinijans VW, Diletti E (1990) A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28:72-78
7. Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, Kunter U (1994) Absolute Bioverfügbarkeit von Chlorpromazin, Promazin und Promethazin. Arzneim-Forsch/Drug Res 44: 121-125
8. Kuemmerle HP, Hitzenberger G, Spitzy KH (1984) Klinische Pharmakologie, 4th edn. Ecomed, Munich
9. Lo ES, Fein M, Hunter C, Suckow RF, Cooper TB (1988) A highly sensitive and specific radioimmunoassay for quantitation of plasma fluphenazine. J Pharm Sci 77:255-258
10. Marder SR, Hubbard JW, Van Putten T, Midha KK (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology 98:433-439
11. Midha KK, McKay G, Edom R, Korchinski ED, Hawes EM, Hall K (1983) Kinetics of oral fluphenazine disposition by GCMS. Eur J Clin Pharmacol 25:709-711
12. Midha KK, Hubbard JW, Marder SR, Hawes EM, Van Putten T, McKay G, May PRA (1987) The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. Psychpharmacology 93:369-373
13. Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1988) Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology (Berlin) 96:206-211